Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.

Robert R HenryDirk Müller-WielandPam R TaubMaja Bujas-BobanovicMichael J LouieAlexia LetierceHenry N Ginsberg

Published in: Diabetes, obesity & metabolism (2018)

Across study pools, alirocumab-associated reductions in LDL-C, apolipoprotein B, and non-HDL-C were significant vs control, and did not vary by MetS status.

Keyphrases

metabolic syndrome
low density lipoprotein
type diabetes
cardiovascular disease
randomized controlled trial
adipose tissue
big data
uric acid
cardiovascular risk factors
skeletal muscle
deep learning
artificial intelligence
weight loss
open label